The device commonly referred to as the “cancer-detecting pen” became internationally known as the MasSpec Pen, a handheld molecular analysis technology developed by Brazilian chemist Lívia Schiavinato Eberlin at the University of Texas at Austin. First publicly presented in 2017, the tool was designed to help surgeons distinguish between healthy and cancerous tissue within seconds during cancer procedures. Years later, its arrival at Hospital Israelita Albert Einstein in São Paulo strengthened the technology’s connection to Brazil by bringing it into clinical evaluation in the country, linking cutting-edge research, Brazilian scientific training, and international visibility in healthcare.

Presence Indicators:

• It has received sustained coverage from universities, science publications, and prestigious foundations, helping establish Lívia Eberlin as one of the most internationally visible Brazilian scientists in her field.
• The technology has progressed from initial demonstrations to clinical studies and intraoperative use across different surgical contexts, including pancreatic and breast procedures.
• The device has also come to represent cutting-edge Brazilian science in news reports, profiles, and science communication materials.
• Its continued technical development and progression toward clinical and commercial applications indicate lasting potential rather than a one-off discovery.